ESLA Estrella Immunopharma, Inc.
$0.82▼ -11.86%
Healthcare
Other
After hours
$0.82▲ +0.10%
Oct 28, 4:51 PM ET
Volume 495.6K
Avg Volume (10D) 9.02M
Key Metrics & Fundamentals
Market Cap
$35.74M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.24 - 3.15
% vs 50 MA
40.41%
% vs 200 MA
-17.13%
RSI-14
62.4
MACD Histogram
+0.0600
Beta (1Y vs SPY)
0.40
Free Cash Flow
-$1.78M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.86M
COGS
–
Operating Exp
$2.08M
Operating Income
-$2.08M
EBIT
-$2.08M
Pretax Income
-$2.31M
Net Income
-$2.31M
EPS (Diluted)
-0.05
Price & Volume History
Loading chart…
Recent News
Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors
Business Wire · Oct 26, 2026 8:00 AM ET
Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
Business Wire · Oct 15, 2026 6:45 PM ET
Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Business Wire · Oct 14, 2026 4:15 PM ET
ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial
Zacks Small Cap Research · Aug 26, 2026 8:42 AM ET
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Business Wire · Aug 11, 2026 8:00 AM ET
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Business Wire · Aug 3, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ESLA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.